All In Biotech

Drug Trial Radar · NCT02267746

A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris

A Multicenter, Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled Study to Evaluate the Safety and Therapeutic Equivalence of a Generic Tazarotene Foam 0.1%(Actavis) and the Reference Listed Fabior™(Tazarotene Foam, 0.1%) (Stiefel Laboratories, Inc.) in Treatment of Subjects With Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Jun 12, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 893 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

893

Actual

Start

Jun 2014

Primary completion

Sep 2014

Study completion Sep 2014

Sponsor

Lead sponsor
Actavis Inc.Industry
Sponsor type
Industry
First posted
Oct 17, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the safety and therapeutic equivalence of a generic tazarotene foam 0.1% and the reference listed Fabior™ (tazarotene foam, 0.1%) in the treatment of acne vulgaris.

Conditions

  • Acne Vulgaris

Interventions

  • Tazarotene (Fabior™)Drug

  • Tazarotene (Actavis)Drug

  • Vehicle foamDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in the Inflammatory (Papules and Pustules) Lesion CountsTime frame: Mean percent change from baseline to Week 12
  2. Percent Change in the Non-inflammatory (Open and Closed Comedones) Lesion CountsTime frame: Mean percent change from baseline to Week 12

Locations

15 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Encino, California

  • Center for Dermatology Clinical Research

    Fremont, California

  • Moore Clinical Research

    Brandon, Florida

  • LCC Medical Research Institute

    Miami, Florida

  • International Dermatology Research

    Miami, Florida

  • FXM Research Corp

    Miami, Florida

  • FXM Research Miramar

    Miramar, Florida

  • Moore Clinical Research

    Tampa, Florida

  • Moore Clinical Research

    Tampa, Florida

  • Atlantic Clinical Research Collaborative

    Wellington, Florida

  • Omega Medical Research

    Warwick, Rhode Island

  • Research Across America

    Dallas, Texas

  • Research Across America

    Plano, Texas

  • Dermatology Research Center

    Salt Lake City, Utah

  • FXM International

    Belize City, Belize

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.